The principal activity of the LLP is to finance, design, build and manage a renewable plant situated in Stoke, for a period of 25 years from May 2020 to April 2045. Whilst construction was completed in February 2023, it has been placed into a state of preservation with future renovation work planned.

The members who served during the year were as follows:

The financial statements have not been prepared on a going concern basis. The LLP has assets attributable to Members of £18,208,623 (2024: £18,356,602).

The members intend to liquidate this LLP after signing and have transferred the assets and liabilities to a new Limited Company in May 2026. As such, these accounts have not been prepared on a going concern basis.

The members are responsible for preparing the Annual Report and annual financial statements in accordance with applicable law and regulation.

Company law, (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008), requires the members to prepare financial statements for each financial year. Under that law the members have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008) the members must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the LLP and of the profit or loss of the LLP for that period.

In preparing these financial statements, the members are required to:

select suitable accounting policies and then apply them consistently;

make judgements and estimates that are reasonable and prudent; and

prepare the annual financial statements on a going concern basis unless it is inappropriate to presume that the limited liability partnership will continue in business.

The members are responsible for keeping adequate accounting records that are sufficient to show and explain the LLP's transactions and disclose with reasonable accuracy at any time the financial position of the LLP and to enable them to ensure that the financial statements comply with the Companies Act 2006 (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of the Companies Act 2006) Regulations 2008). They are also responsible for safeguarding the assets of the LLP and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report was approved by the members of the limited liability partnership on 16 September 2026 and signed by:

In order to assist you to fulfil your duties under the Companies Act 2006 as applied to limited liability partnerships by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008, we have prepared for your approval the annual financial statements of Clinitek (Stoke) LLP for the year ended 31 December 2025 which comprise the statement of comprehensive income and statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.

This report is made solely to the designated members of Clinitek (Stoke) LLP, as a body, in accordance with the terms of our engagement letter dated 19 June 2025. Our work has been undertaken solely to prepare for your approval the accounts of Clinitek (Stoke) LLP and state those matters that we have agreed to state to the designated members of Clinitek (Stoke) LLP, as a body, in this report in accordance with the requirements of ICAS as detailed at https://icas.com/icas-framework-preparation-of-accounts. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Clinitek (Stoke) LLP and its designated members as a body for our work or for this report.

It is your duty to ensure that Clinitek (Stoke) LLP has kept adequate accounting records and to prepare annual financial statements that give a true and fair view of the assets, liabilities, financial position and profit or (loss) of Clinitek (Stoke) LLP. You consider that Clinitek (Stoke) LLP is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the annual financial statements of Clinitek (Stoke) LLP. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the annual financial statements.

These annual financial statements have been prepared in accordance with the provisions applicable to LLPs subject to the small LLPs regime.

For the year ended 31 December 2025, the limited liability partnership was entitled to exemption from audit under section 477 of the Companies Act 2006 (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008) relating to small LLPs.

The members have not required the company to obtain an audit of its accounts for the year ended 31 December 2025 in accordance with section 476 of the Companies Act 2006 (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008).

The members acknowledge their responsibility for complying with the requirements of the Companies Act 2006 (as applied to limited liability partnerships) with respect to accounting records and the preparation of accounts.

The annual financial statements were approved and authorised for issue by the members on 16 September 2026.

Signed on behalf of the designated members of Clinitek (Stoke) LLP:

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006 and the requirements of the Statement of Recommended Practice "Accounting by Limited Liability Partnerships".

The financial statements are prepared in sterling, which is the functional currency of the limited liability partnership. Monetary amounts in these financial statements are rounded to the nearest £.

The following principal accounting policies have been applied:

The financial statements have not been prepared on a going concern basis. The LLP has assets attributable to Members of £18,208,623 (2024: £18,356,602).

As stated above, it is the intention of the members to liquidate this LLP after signing and transfer the assets and liabilities to a new Limited Company. As such, these accounts have not been prepared on a going concern basis.

Members' participation rights are the rights of a member against the LLP that arise under the members' agreement (for example, in respect of amounts subscribed or otherwise contributed remuneration and profits).

Members' participation rights in the earnings or assets of the LLP are analysed between those that are, from the LLP's perspective, either a financial liability or equity, in accordance with section 22 of FRS 102. A member's participation rights including amounts subscribed or otherwise contributed by members, for example members' capital, are classed as liabilities unless the LLP has an unconditional right to refuse payments to members, in which case they are classified as equity.

Profits are divided only after a decision by the LLP or its representative, so the LLP has an unconditional right to refuse payment. Such profits are classed as equity rather than as liabilities. They are therefore shown as a residual amount available for discretionary division among members in arriving as the result for the year and are shown as appropriations of equity when they are allocated.

Losses are allocated between the Members in their relevant proportions, restricted to the capital contributions, and shall be classified as equity rather than liabilities. The Members are not required to make additional contributions to cover any potential losses.

All amounts due to members that are classified as liabilities are presented within 'Loans and other debts due to members' and, where such an amount relates to current year profits, they are recognised within 'Members' remuneration charged as an expense' in arriving at the relevant year's result. Undivided amounts that are classified as equity shows within 'Members' other interests'. Amounts recoverable from members are presented as debtors and shows as amounts due from members within members' interests.

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the LLP and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Interest income is recognised in profit or loss using the effective interest method.

Tangible fixed assets under the cost model are stated at historical cost less any impairment loss. Cost includes professional fees and other attributable costs that are necessary to bring the asset to its operating condition.

No depreciation has been provided on the asset still under construction at the Balance Sheet date, and the members will continue not to do so until the plant becomes operational.

Assets that are subject to depreciation or amortisation are assessed at each balance sheet date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each balance sheet date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Exceptional income represents a waiver of the member loan balances on the date of the sale of £nil (2024: £16,478,524).

In May 2026, the LLP underwent a restructuring whereby Stoke City Technologies BidCo 1 Limited transferred its membership interest to Clinitek Energy Ltd, and the loan receivable owed by the LLP to Stoke City Technologies BidCo 1 Limited was transferred to Clinitek Energy Ltd. As part of the restructuring, the LLP transferred all assets to Clinitek Energy Ltd under an Asset Transfer Agreement which also resulted in Clinitek Energy assuming the LLP's liabilities. The asset transfer satisfied in full the intercompany debt owed by the LLP to Clinitek Energy Limited. The LLP is expected to undertake a members' voluntary liquidation or voluntary strike-off at a later date.

Clinitek Energy Limited became a member post year end following the resignation of Stoke City Technologies Bidco 1 Limited. Any obligations to Stoke City Technologies Bidco 1 Limited as at the year end were transferred to Clinitek Energy Limited.

The LLP incurred other income of £524,940 (2024: £nil) for the sale of spares to Trans-Euro Pte Ltd, reg 199104806N, 55 Pioneer Road, Singapore 6862 1245.

As at the year end the ultimate controlling party is A Singh.